ProShare Advisors LLC - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.

Quarter-by-quarter ownership
ProShare Advisors LLC ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$262,046
+0.9%
37,012
+0.4%
0.00%0.0%
Q2 2023$259,621
-10.8%
36,878
+5.7%
0.00%0.0%
Q1 2023$291,041
-35.5%
34,897
-11.2%
0.00%
-50.0%
Q4 2022$450,992
-0.9%
39,285
+8.9%
0.00%0.0%
Q3 2022$455,000
+21.7%
36,083
+2.2%
0.00%
+100.0%
Q2 2022$374,000
-56.5%
35,293
-33.2%
0.00%
-50.0%
Q1 2022$860,000
-3.8%
52,869
-18.1%
0.00%0.0%
Q4 2021$894,000
+1.9%
64,573
+5.9%
0.00%0.0%
Q3 2021$877,000
-28.9%
60,998
-21.9%
0.00%
-50.0%
Q2 2021$1,234,000
+69.3%
78,054
+8.9%
0.00%
+100.0%
Q1 2021$729,000
+47.3%
71,674
+8.0%
0.00%0.0%
Q4 2020$495,000
+187.8%
66,380
+32.5%
0.00%
+100.0%
Q3 2020$172,000
-25.9%
50,107
+3.1%
0.00%0.0%
Q2 2020$232,000
+286.7%
48,619
+61.0%
0.00%
Q1 2020$60,000
-67.4%
30,205
-43.4%
0.00%
-100.0%
Q4 2019$184,000
+50.8%
53,393
+25.8%
0.00%0.0%
Q3 2019$122,000
-26.5%
42,441
-3.0%
0.00%0.0%
Q2 2019$166,000
-58.5%
43,755
-10.9%
0.00%
-50.0%
Q1 2019$400,000
+1.8%
49,111
+0.9%
0.00%
-33.3%
Q4 2018$393,000
-11.1%
48,660
-16.0%
0.00%0.0%
Q3 2018$442,000
+41.7%
57,953
+6.3%
0.00%
+50.0%
Q2 2018$312,000
+12.6%
54,502
-6.1%
0.00%0.0%
Q1 2018$277,000
-16.6%
58,035
-14.1%
0.00%0.0%
Q4 2017$332,000
+24.8%
67,561
+33.0%
0.00%0.0%
Q3 2017$266,000
-1.1%
50,807
+5.1%
0.00%
-33.3%
Q2 2017$269,000
-33.3%
48,354
+0.9%
0.00%
-25.0%
Q1 2017$403,000
+5.2%
47,927
-20.8%
0.00%0.0%
Q4 2016$383,000
+61.6%
60,527
+12.6%
0.00%
+33.3%
Q3 2016$237,000
+30.9%
53,737
-15.8%
0.00%
+50.0%
Q2 2016$181,000
+1.7%
63,843
+1.4%
0.00%0.0%
Q1 2016$178,000
-75.2%
62,967
-9.4%
0.00%
-77.8%
Q4 2015$718,000
+0.3%
69,532
+10.8%
0.01%
-10.0%
Q3 2015$716,000
-28.5%
62,777
-6.4%
0.01%
-28.6%
Q2 2015$1,002,000
+55.3%
67,096
-6.1%
0.01%
+75.0%
Q1 2015$645,000
-15.2%
71,441
+14.2%
0.01%
-11.1%
Q4 2014$761,000
+20.2%
62,577
-3.3%
0.01%
+12.5%
Q3 2014$633,000
-35.2%
64,742
-15.5%
0.01%
-38.5%
Q2 2014$977,000
+104.0%
76,608
+69.4%
0.01%
+116.7%
Q1 2014$479,000
+143.1%
45,235
+74.7%
0.01%
+100.0%
Q4 2013$197,000
+264.8%
25,886
-25.2%
0.00%
+200.0%
Q2 2013$54,00034,5990.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q3 2023
NameSharesValueWeighting ↓
VHCP Management, LLC 1,744,356$18,455,0009.59%
RA Capital Management 4,347,456$45,996,0003.30%
Cormorant Asset Management, LP 1,168,000$12,357,0002.84%
Baker Brothers Advisors 5,867,031$62,073,0000.79%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 907,920$9,606,0000.39%
QVT Financial LP 525,734$5,562,0000.32%
EAM Investors, LLC 114,548$1,212,0000.22%
FRANKLIN STREET ADVISORS INC /NC 93,000$984,0000.20%
THB ASSET MANAGEMENT 301,529$3,190,0000.19%
TPG Group Holdings (SBS) Advisors, Inc. 1,162,269$12,297,0000.13%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders